Advances in Hematology Research & Patient Care (January 2016, Volume 2, Issue 1.1)

January 2016 Special Edition

Volume 2, Issue 1.1

This special edition takes a deep dive into coverage from the 2015 ASH Annual Meeting, including interviews with speakers and up-to-date clinical findings presented at the meeting.

Table of Contents

Advances in Hematology Research & Patient Care

Translating Genetic Information to Hematologic Care: An Interview with Jill Johnsen, MD

Friday, January 1st, 2016
The recent exponential growth of DNA sequencing capabilities has given hematologists unprecedented views of the human genomic landscape and, with that information, the potential...

Future Directions and Challenges in Treating Sickle Cell Disease: An Interview with Griffin Rodgers,...

Friday, January 1st, 2016
Patients with sickle cell disease (SCD) face chronic and often debilitating complications, but have limited treatment options. Several presentations at this year’s ASH annual...

Advances in Hematology Research & Patient Care

Pracinostat Added to Azacitidine in Previously Untreated MDS: No Clinical Benefit, But Added Toxicity

Friday, January 1st, 2016
Results from a multicenter, placebo-controlled study presented by Guillermo Garcia-Manero, MD, at the ASH annual meeting last month, demonstrated that the oral histone deacetylase...

Genetic Variants Predict Osteonecrosis in Children with ALL

Friday, January 1st, 2016
Pediatric patients with acute lymphocytic leukemia (ALL) and chemotherapy-induced osteonecrosis are significantly more likely to possess certain genetic variants near genes essential to bone...

N-Acetylcysteine Increases Platelet Counts in Patients with Thrombotic Thrombocytopenia Purpura

Friday, January 1st, 2016
Thrombotic thrombocytopenic purpura (TTP) is a rare hematologic disorder caused by a deficiency of plasma ADAMST13 and systemic microvascular occlusion from von Willebrand factor...

Eltrombopag Increases Platelet Counts in Patients with Lower-Risk MDS and Thrombocytopenia

Friday, January 1st, 2016
For the 10 percent of patients with lower-risk myelodysplastic syndromes (MDS) who experience severe thrombocytopenia, there are few options for therapies to increase platelet...

Hemoglobin Modifier GBT440: A New Option for Patients with Sickle Cell Disease

Friday, January 1st, 2016
Patients with sickle cell disease (SCD) who received GBT440, a novel oral small molecule hemoglobin modifier, had a reduction in sickle cells, a reduction...

ELOPE: A Look at Patient-Centered Outcomes One Year After Pulmonary Embolism

Friday, January 1st, 2016
One year after a pulmonary embolism (PE), patients tend to have less dyspnea, better quality of life (QOL), and improved walking capacity compared to...

Results from the Lumiere Trial: Shining a Light on Alisertib in Relapsed/Refractory PTCL

Friday, January 1st, 2016
Patients with relapsed and/or refractory peripheral T-cell lymphoma (PTCL) have limited treatment options, and, subsequently, poor survival outcomes. Alisertib, an investigational oral selective inhibitor...

Brentuximab Vedotin Plus Dacarbazine or Bendamustine: New Options for Older Patients with Hodgkin Lymphoma?

Friday, January 1st, 2016
Older patients with Hodgkin lymphoma (HL) often don’t tolerate standard chemotherapy regimens and have worse outcomes compared with younger patients. While previous studies have...

Over-Reporting of At-Home Chemotherapy Adherence Using Self-Reporting Methods: Improving 6MP Maintenance in Pediatric Patients...

Friday, January 1st, 2016
Although it is the most convenient method for monitoring oral 6-mercaptopurine (6MP) intake in pediatric patients with acute lymphocytic leukemia (ALL), self-reporting frequently becomes...

RESONATE-2: Ibrutinib Safe, Effective in Older Patients with CLL/SLL

Friday, January 1st, 2016
Chlorambucil is considered a standard therapy for older patients with chronic lymphocytic leukemia (CLL) but, according to results from the RESONATE-2 trial presented at...

Early PET Scans Can Safely Guide Chemotherapy De-Escalation in Patients with Hodgkin Lymphoma

Friday, January 1st, 2016
Although escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), or BEACOPPesc, has been shown to be superior to ABVD chemotherapy in controlling...

SHARE